Leitner G C, Baumgartner K, Kalhs P, Biener D, Greinix H T, Hoecker P, Worel N
Department of Transfusion Medicine, Medical University of Vienna, Vienna, Austria.
Bone Marrow Transplant. 2009 Mar;43(5):357-63. doi: 10.1038/bmt.2008.335. Epub 2008 Oct 20.
Mobilized allogeneic PBPC are increasingly used instead of BM for allogeneic stem cell grafting. Although the short-term safety profile of recombinant human (rh)G-CSF seems acceptable, only minimal data on long-term safety are available. We therefore reviewed data on 171 sibling donors (M/F: 98/73) with respect to side effects of rhG-CSF and PBPC collection and impact on quality of life (QoL) and health status. In a cross-sectional study, we investigated the actual QoL and health status of the donors as well as the need for medical treatment since PBPC donation by a questionnaire that was sent to 151 donors. Ninety-five (64%) of the addressed donors responded to the questionnaire, but only 69 (46%) of them reported on their actual health status and QoL, which was good to very good in the majority of them. Two donors developed malignancies in the post-donation course. In general, PBPC collection after rhG-CSF mobilization was well tolerated by the responding donors. Although the reported events in medical history after PBPC donation do not seem to be associated with rhG-CSF administration or the collection procedure, a lifelong follow-up of donors should be obligatory.
动员后的异基因外周血造血干细胞（PBPC）越来越多地被用于替代骨髓进行异基因干细胞移植。尽管重组人（rh）粒细胞集落刺激因子（G-CSF）的短期安全性似乎可以接受，但关于其长期安全性的数据却非常有限。因此，我们回顾了171名同胞供者（男/女：98/73）关于rhG-CSF的副作用、PBPC采集以及对生活质量（QoL）和健康状况影响的数据。在一项横断面研究中，我们通过向151名供者发送问卷，调查了供者的实际QoL和健康状况以及自PBPC捐献以来的医疗需求。95名（64%）被调查的供者回复了问卷，但其中只有69名（46%）报告了他们的实际健康状况和QoL，大多数人的情况良好至非常好。两名供者在捐献后出现了恶性肿瘤。总体而言，rhG-CSF动员后的PBPC采集在回复问卷的供者中耐受性良好。尽管PBPC捐献后报告的病史事件似乎与rhG-CSF给药或采集程序无关，但对供者进行终身随访是必要的。
